and Enteral Nutrition) published guidelines regarding nutritional support of patients with hematologic stem cell transplantation. Our aim was to do an up-to-date literature review regarding benefit of nutritional interventions and treatment recommendations. We searched MEDLINE, EMBASE and Cochrane Library for interventional and observational clinical studies. We extracted data based on a predefined case report form and assessed bias. Out of 459 potential abstracts, 13 studies of mostly moderate quality with a total of 18 167 patients were included. Two very large trials reported negative associations of malnutrition and survival, transplant-related mortality and relapse risk. Some trials found enteral nutrition (EN) to be as effective as parenteral nutrition (PN) with lower complication rates. In addition, EN was associated with better survival, less acute GvHD and faster neutrophil recovery. A neutropenic diet was not superior regarding overall survival, but in contrast resulted in higher infection risk. Current moderate quality studies show negative associations of malnutrition and clinical outcomes, with EN being superior to PN. There was no benefit of neutropenic diets. Large, randomized controlled studies are needed to better understand optimal nutritional support in this patient population.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) after myeloablative and non-myeloablative conditioning is currently the only potentially curative treatment for several hematologic malignancies, including acute leukemia. Its importance still increases due to improved outcome based on marked changes in treatment regimen. 1 Hence, the regimen is physically demanding and requires optimal health and nutritional conditioning before the start of treatment. Several factors are known to influence disease outcome such as type of leukemia, disease stage, conditioning regime, type of stem cell transplantation (autologous/allogeneic/haploidentical), stem cell source (peripheral blood, bone marrow or cord blood), prior treatment and patient age. 2 Notably, impaired nutritional status before and during transplantation is thought to be an important factor that is potentially modifiable through nutritional support.
Most patients start treatment in a relatively healthy nutritional state [3] [4] [5] but experience a rapid deterioration on treatment. 6, 7 This may be explained by the direct toxic effects of treatments, or may be due to secondary complications such as infections and acute GvHD. Chemotherapy-related side effects lead to mucositis with pain, limited gut absorption and anorexia, all of which affect dietary intake. 8, 9 Moreover, the incidence of chemotherapyinduced toxicity is higher in malnourished patients. 10 Acute and chronic GvHD, as well as infectious complications, correlate with decreased oral intake and poor nutritional status. [11] [12] [13] To circumvent these adverse outcomes, adequate nutritional support before and during treatment is a potentially important supportive measure. However, there is ongoing controversy about its added benefit. In 2009, large societies such as the American Society for Parenteral and Enteral Nutrition and the European Society for Parenteral and Enteral Nutrition issued guidelines on nutritional support in patients undergoing HSCT. [14] [15] [16] In addition, it was recommended that enteral nutrition (EN) should be the first option and preferred over parenteral nutrition (PN) due to the higher risk of side effects such as central line infections and metabolic complications. PN was only recommended in cases of severe mucositis (4grade 3) or gastrointestinal failure. These recommendations are also supported by an independent Cochrane meta-analysis published in 2008. 17 Owing to weak evidence for all recommendations, there is broad variability of current clinical practice guidelines, as well as discrepancy between hospital guidelines and international recommendation. [18] [19] [20] Many centers also lack a standardized strategy for nutritional support in these patients.
Since the publication of these guidelines in 2009, important studies on the role and impact of nutritional interventions on clinical outcomes in patients undergoing HSCT have been published. We undertook a systematic up-to-date literature review focusing on the years 2009-2015. We focused on three main questions: the association between malnutrition and clinical outcomes, the effect of nutritional interventions on outcome and the role of a neutropenic diet. Eligibility criteria Randomized clinical and observational studies investigating nutritional support in adults undergoing allogeneic HSCT were considered eligible for inclusion in this review. We only included studies published after 2009, which were not included in the American Society of Parenteral and Enteral Nutrition and Euopean Society for Parenteral and Enteral Nutrition guidelines. We did not include case reports, narrative reviews, surveys, animal studies and unpublished records. In addition, we decided to focus on adult patients receiving allogeneic transplantation, thereby excluding trials in pediatric patients or autologous transplanted subjects. Of note, we also included one study in a mixed patient group of allogeneic as well as autologous transplant patients.
MATERIALS AND METHODS
Information sources and search strategy The PubMed/MEDLINE and EMBASE databases and Cochrane Central Registry of Controlled Trials were searched in January 2015, in cooperation with a subject specialist of the University Library of the University of Basel, in order to identify all published work on the topics of interest. The searches were performed using keywords and Medical Subject Headings terms. We combined two search terms to cover the subject nutrition and the procedure in question. The full electronic search protocol is presented in the Supplementary Appendix Search Terms.
Study selection and date collection process Eligibility assessment was performed by one of the authors (AB) in discussion with the study team. All search results were assessed through a short review of abstracts. Studies meeting the inclusion criteria were read in full. For data extraction, a predefined case report form was used following a testing period. During the process of data extraction, the individual risk of bias of each study was assessed by two independent reviewers, using Scottish Intercollegiate Guidelines Networkchecklists. Final extraction results were checked and discussed among the research team.
From each included trial we extracted the following information: (1) name, year and title of the trial; (2) number of included patients and patient characteristics (allogeneic/ autologous, adult/children); (3) study design; (4) main focus; (5) main results including information concerning our main investigation questions; (6) conclusions; and (7) limitations.
Data synthesis and analysis
Owing to the lack of quantitative data and the wide heterogeneity among trials, we decided not to perform a quantitative metaanalysis, but rather focused on presentation of data qualitatively corresponding to each of the four objectives stated above.
RESULTS
Studies identified through the search strategy Our systematic search, which was performed in January 2015, identified 459 titles and abstracts of potentially eligible studies through database searching (Supplementary Figure 1) . After removal of duplicates and elimination of records with a different focus according to their title, 205 records were screened and 72 full text references were assessed. Thirteen studies with a total of 18 167 patients were included in the final review.
Study characteristics and risk of bias Most of the included studies were small, single-center studies that included adult patients with different hematological diseases ( Tables 1 and 2 ). As for bias assessment (Supplementary Table 2 ), most studies were only of moderate quality and were associated with high risk of bias due to the observational nature of the studies or the retrospective study design used. Tables 1 and 2 show an overview of included studies stratified according to our four study questions. A total of 10 studies focused on the association of malnutrition and clinical outcome (Table 1) with two studies having very large numbers of patients (n = 12 050 and n = 4215). Malnutrition was mainly assessed by means of body mass index (BMI) and weight loss. All included studies reported a similar finding, namely that the majority of patients are well nourished before HSCT, despite having received induction chemotherapy. All studies focusing on a post-transplant follow-up also reported weight loss during HSCT in the range of 5-10% of initial BMI or 5-10% of pre-transplant body weight. A total of six studies containing the majority of all patients (490%) also showed a negative association of malnutrition (defined by low BMI o18.5 kg/m 2 ) and clinical outcome, mainly OS. The studies authored by Sucak et al., 21 Sommacal et al., 22 Rieger et al., 23 Ruiz-Delgado et al. 24 and Habjibabaie et al. 25 did not report significant negative associations, but these studies were small in size.
Association of malnutrition and clinical outcome
The study authored by Navarro et al. 26 including a very large patient population (n = 4215) also reported a significant increase in transplant-related mortality (relative risk (RR) 2.23; 95% confidence intervals: 1.17-4.25; P = 0.014) in malnourished and underweight patients. In this study, underweight was also associated with higher relapse rate but slightly lower nonrelapse mortality compared with normal-weight patients. In the study by Navarro et al. (n = 4215), 26 underweight was associated with higher overall and transplant-related mortality, and higher relapse risk. No difference in the occurrence of GvHD was found.
Does nutritional support provide a benefit on outcome with respect to OS? And if treated, should EN or PN be favored? There was no trial assessing the effect of nutritional support per se compared with not providing nutritional support. This might be explained by the potential ethical questions such a study would face. Yet, two studies evaluated differences between using EN and PN using an observational study design (Table 2 ). In both studies, patients were offered EN, but could decline and instead be treated by PN. In the study authored by Seguy et al., 27 94 of 121 patients were initially enrolled in the EN arm, but 31 patients needed PN later because of insufficient tube tolerance. A total of 61 patients (50% of all patients) were fed by EN alone. After propensity score adjustment, the study found better clinical outcomes in the EN group with regard to OS, neutrophil engraftment and acute GvHD Revisiting nutritional supportdevelopment. In the study by Guièze et al., 28 EN was associated with a lower median duration of fever, a reduced need for empirical antifungal therapy, a lower rate of central venous catheter replacement and a lower rate of transfer to an intensive care unit. Yet, there was no difference in the mortality rate at day 100.
What is the role of a neutropenic diet? Our search found one retrospective, observational study that evaluated the effect of neutropenic diet on the outcome of patients in a mixed 75% autologous and 25% allogeneic transplant population (Table 2 , lower part). The study compared patients in a hospital that changed its protocol from a neutropenic diet to a modified hospital diet in 2006. Patients treated before 2006 received a neutropenic diet (excluding fresh fruit and vegetables, raw and undercooked meat and cheese, cold smoked fish, raw grain products or unpasteurized dairy products), whereas patients treated after 2006 faced fewer restrictions (that is, no uncooked meat, fish or unpasteurized dairy products). The authors reported significantly more microbiologically confirmed infections Abbreviations: allo-HSCT = allogeneic hematopoietic stem cell transplantation; BMI = body mass index; CI = confidence interval; EFS = event-free survival; HR = hazard ratio; LBMI = lean body mass index; LOS = length of stay; MAC = myeloablative conditioning; NRM = non-relapse mortality; NW = normal weight; OS = overall survival; RD = related donor; RR = relative risk; TRM = transplant-related mortality; UW = underweight. Abbreviations: allo-HSCT = allogeneic hematopoietic stem cell transplantation; auto-HSCT = autologus hematopoietic stem cell transplantation; CI = confidence interval; EC = erythrocyte; EN = enteral nutrition; GI = gastrointestinal (tract); HR = hazard ratio; ICU = intensive care unit; MAC = myeloablative conditioning; ND = neutropenic diet; OS = overall survival; PLT = platelet; PN = parenteral nutrition; RIC = reduced-intensity conditioning.
in patients receiving neutropenic diet during hospitalization and especially after recovery from neutropenia. Urinary tract infections and infections originating from a gastrointestinal source (vancomycin-resistant Enterococcus faecium, Enterobacteriacea, Clostridium difficile) were also more common. There was no difference between the groups in terms of mortality. 29 
DISCUSSION
Our systematic search for studies published after the international guidelines were released in 2009 found 459 studies of which 13 met our eligibility criteria and were included in this report. Overall, the studies had only moderate to low quality mainly due to an observational or retrospective design and the absence of randomization. The evidence generated by this updated search confirms previous notions that malnutrition is associated with adverse clinical outcome and is therefore worthy of further investigation. Although no trial has questioned whether nutritional therapy has a benefit at all compared with not providing nutritional therapy in these patients, studies have compared EN with PN, with the enteral route showing superior results and moderate to high tube tolerance. Finally, regarding the neutropenic diet, recent studies have not supported that restricted diets would have any additional benefit over less stringent diets but rather result in worse infectious complications. The vast majority of patients ready to undergo HSCT is well nourished, with a median BMI of 25 kg/m 2 despite prior induction chemotherapy. [21] [22] [23] During further treatment, weight loss reaches 5-10% of initial body weight or initial BMI. 3, 7, 23, 30 Weight loss and low body weight among others are accepted parameters used to determine malnutrition. [31] [32] [33] Both parameters lack information on body composition, which is considered to be of importance for survival. 34 Owing to conflicting data, there is still no consensus on which parameters best determine malnutrition, show a correlation with clinical outcomes and are reproduceable as well as easy to use in clinical practice. 3, 8, 35 Along with body composition, there is increasing interest in the effect of exercise on maintenance of muscle mass and survival. In patients undergoing stem cell transplantation, there is a trend to better quality of life, stabilized muscle mass and better functional outcome. [36] [37] [38] [39] Yet, there is no association of exercise and improved survival so far. 37 Malnutrition itself has been demonstrated to be an independent risk factor for poor outcome in HSCT before and is supported by our findings.
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However, it is unclear at this time as to whether malnutrition is indeed an independent risk factor that is modifiable through adequate nutritional treatment or rather a mirror of the underlying disease, with worse disease course leading to deterioration of nutritional status. Large trials comparing head-to-head a nutritional therapy with no therapy (for example, placebo or hydration) are largely lacking. Since the randomized trial performed by Weisdorf et al., 41 which found decreased mortality with PN, the practice to treat manifest or imminent malnutrition mainly by PN is well established and recommended by current international guidelines. 3, 14, 11, 40, 42 Still, the results by Weisdorf et al. 41 have not been confirmed by others later. Owing to lack of benefit, the prophylactic use of PN is not recommended. 15, 17 There is also no evidence-based consensus about which parameters best define the indication for nutritional support. 18 Yet, most authors in current literature do recommend (high caloric) nutritional support with decreasing oral intake. 43, 44 Our updated search retrieved no trial comparing nutritional therapy (either EN or PN) with intravenous hydration in regard to mortality and morbidity benefits. PN seems to preserve weight and especially body fat mass; hence, nutritional status might be better preserved. 3, 14, 45, 46 In a study performed in the general population of Gothenburg, Sweden, Heitmann 47 showed a linear association of mortality with increasing body fat mass and decreasing lean body mass. Fat-free mass as well seems to correlate better with functional capacity as forced expiratory volume and the 6 min walking test and mortality compared with fat mass or BMI. 46, 47 In addition, PN itself is associated with important side effects, mainly central line infections, and therefore careful risk-benefit-analysis has to be made. 14, 15, 17 Despite the lack of strong trial data supporting the use of nutritional therapy, such nutritional interventions are an integral part of international guidelines and form a part of supportive care in stem cell transplantation around the world. [13] [14] [15] 41, 42 For ethical reasons, however, it may be difficult to challenge this issue. However, not only medical staff but patients as well do have a specific concept of nutritional support. Kiss et al. 6 found important conflict between the concepts of patients and medical recommendations, limiting feasibility of nutritional interventions.
In clinical practice, PN is often favored over EN due to practical reasons such as challenging gastrointestinal symptoms, tube feeding problems and unknown degree of malabsorption. 48, 49 Both feasibility as well as safety of EN have been shown in several small studies. In a statistically adjusted analysis reported by Seguy et al., 27 higher OS, lower rates of acute GvHD and an association with earlier neutrophil engraftment were found when EN was used compared with PN. Adherence to nasogastric tube feeding has been demonstrated to be achieved in 50-90% of patients. 27, 28, 48, 50 Especially in children, EN has been shown to be a valuable alternative for PN in most patients. 23, 42 Owing to its less invasive nature and the arguments cited above, there is therefore consensus that EN should be preferred over PN, except for cases of gastrointestinal failure or tube-feeding intolerance.
There are different initiatives focusing on ways to better implement EN into clinical routine, mainly by the release of hospital guideline recommendations. 20 These first results support current efforts to further investigate the value of EN in large, prospective randomized controlled trials as the ongoing study authored by Lemal et al.
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Current literature also questions the role of antioxidants, mainly glutamine, vitamins, trace elements and immunomudulants, for example, omega 3 fatty acids. [52] [53] [54] [55] [56] Except for vitamin D, there is no proven benefit of those substances. 57, 58 Unfortunately, there were no studies of high quality to integrate into this review.
In addition to improving nutritional status, there is ongoing controversy about the risk of infections associated with food sources, leading to the concept of a neutropenic diet. The benefit of a neutropenic diet was from the start based on theoretical considerations rather than on clinical trial data. 59, 60 Since the beginning of transplantation during the 1970s, there was a mind shift from very strict diets to less restrictive diets mainly due to lack of evidence and persisting clinical outcomes. 59, 61 High costs and doubts about the effectiveness of neutropenic diets have been a major barrier to their routine implementation. 62 We also found one large trial authored by Trifilio et al., 29 which did not find negative effects after introducing raw fruits and vegetables in terms of infection rate and mortality. Yet, they reported higher infection rates in patients receiving a neutropenic diet. 29 This result in combination with previous similar observations argues for a less strict use of neutropenic diets. [59] [60] [61] [62] [63] [64] [65] [66] [67] Therefore, focusing on safe food-handling practices and retaining restrictions on raw meat or dairy products, as well as apparent fungal components as mold cheese, but allowing raw fruit and vegetable if properly washed and/or peeled seems adequate. 61, 68 Again, only adequately powered randomized controlled studies will give better evidence on effectiveness of food safety guidelines.
Not only protection from harmful bacteria, viruses and fungi but the protection of adjuvant forms has come into focus of current research. The microbiome with preserved variability of species might be of interest to improve nutrition. 69 Especially in GvHD, maintenance of a healthy microbiome might be of importance. 69 There are pre-studies examining the effect of prebiotics and Revisiting nutritional supportprobiotics on the micriobiome in the transplant population. 70, 71 Thus far, no benefit of these substances has been documented.
During revision of our review in September 2016, some additional studies qualifying for analysis have been published. Yet, our main findings would not be changed by their findings. Therefore, we did not fully integrate them into our work. A retrospective analysis by Espinoza et al. 72 did not show a correlation of nutritional parameters with survival. Yet, high catabolism, expressed by laboratory parameters as albumin or nitrogen balance, was associated with longer hospital stay. 72 Our own retrospective study did as well show a correlation of high weight loss during the index hospitalization and increased morbidity and length of hospital stay. 73 However, we also found an association of low pretransplantation body weight with mortality. 73 The result is supported by Xue et al. 74 documenting lower survival in underweight patients before transplantation in another retrospective analysis. Dietrich et al. 75 examined the association of BMI before the beginning of induction chemotherapy and BMI before transplantation with survival. There was no deterioration of survival by low BMI at either of the examined time points. 75 However, there was significant increase in relapse risk correlating with higher weight loss. 75 In contrast to Navarro et al., 26 Gleimer et al. 76 reported a decreased survival in obese patients before transplantation. Owing to low numbers of underweight patients in their population, no statement on the association of underweight and mortality could be done. 76 There was one study comparing survival of patients needing oral nutritional support to patients receiving EN. 77 Unfortunately, its design as a retrospective cohort study limits its significance. There was no arm of pure hydration or PN. The authors documented poorer survival for patients receiving EN in comparison with patients receiving oral nutritional support. 77 Anderson et al. 78 analyzed the feasibility of nasogastric tubes in adults. The importance of this trial is limited by a very small population size of patients. Concerning neutropenic diet Taggert et al. 79 did not find an increase of central line infections when using safe food handling instead of their routine low bacterial diet. A correlation with survival unfortunately is missing, as well as details on their safe food handling strategy. 79 Iyama et al.
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studied the effect of an enteral supplementation enriched with glutamine, fiber and oligosaccharides on mucositis. Forty-four patients were compared with a historic control group. 80 Cumulative days of diarrhea were reduced. There was no effect on severity of mucositis nor survival. 80 
CONCLUSION
Our updated search found strong associations between malnutrition and negative clinical outcomes. Owing to the lack of randomized trials, causality was not proven. Considering the important side effects of PN, current evidence points to a beneficial role of EN as a first choice. Stricter neutropenic diets did not show any benefit on infection rates or survival, which argues against their routine use. To address the issue of only moderate to low quality studies being retrieved by our search, large-scale randomized controlled trials are urgently needed to explore optimal nutritional strategies for this patient population.
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